3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
28
Phase 1/2
22
Phase 2
14
Phase 3
4
Phase 2/3
1
Status
Recruiting
8
Not yet recruiting
5
Active not recruiting
2
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Carboplatin
9
Paclitaxel
8
Gemcitabine
8
Cisplatin
8
Cyclophosphamide
7
Fluorouracil
6
Docetaxel
5
Capecitabine
5
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Vinorelbine
3
Stem Cell Transplantation
3
Radiotherapy
3
Pemetrexed
3
Melphalan
3
Leucovorin
3
Filgrastim
3
Erlotinib Hydrochloride
3
Bone Marrow Transplantation
3
Bevacizumab
3
umbralisib
2
ublituximab
2
pembrolizumab
2
peginterferon alfa-2b
2
fludarabine
2
Whole-Body Irradiation
2
Trastuzumab
2
Transplantation, Homologous
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Terminated
×
venetoclax
×
Clear all
NCT03801525
2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3
Terminated
277 enrolled
19 charts